Conclusion: PD US inflammatory findings are found in 1 over 3 patients with IA being PD synovitis the most common finding, specially at the wrists and MCP joints. Higher ESR values were significantly associated with the presence of US inflammatory findings. Our data highlights how the use of PD US may be useful to detect subclinical synovitis in patients with IA.

Disclosure of Interests: Katherine López Gloria: None declared, Isabel Catribron: None declared, Laura Trives Folguera Speakers bureau: Abbvie, Celgene, Filip, Janssen, Novartis, Pfizer, Roche, Sanofi, Serrano Benavente: None declared, Javier Rivera: None declared, Carlos Gonzalez Consultant of: Lilly, Pfizer, Roche, Takeda, MSD, Pfizer

Email: david@canalismo.com

Results: Meta-analysis revealed that the levels in serum of IgG autoantibodies against Centromere protein F (CENPF) are significantly increased in responders (good responders and moderate responders; N=111) to IFX compared to non-responders (N=44) (P=0.018). CENPF is a proliferation-associated and cell cycle-dependent centromere autoantigen that might be involved in the increased or abnormal cell proliferation that occurs during RA process. The combination of the anti-CENPF antibodies with clinical variables (age, sex, DAS28-ESR) resulted in the best model to discriminate the patients that will respond to IFX, showing an AUC of 0.756 (95% CI [0.639-0.874], P<0.001).

Conclusion: High serum levels of IgG anti-CENPF antibodies might be potentially useful to identify RA patients more likely to benefit from IFX.

Disclosure of Interests: Lucia Lourido: None declared, Cristina Ruiz-Romero: None declared, M. Molina Collada: None declared, flor picchi: None declared, Naomi Diz-Rosales: None declared, Sergio Vilaboa-Galán: None declared, Carlos Fernández-López: None declared, Jose Antonio Pinto Tascande: None declared, Eva Perez-Pampin: None declared, Cristina Reveiro Exposito: None declared, ANTONIO MERA VARELA: None declared, Antonio Gonzalez: None declared, Karen Hambardzumyan: None declared, Saedis Saevardsdottir Employee of: Part-time at deCODE Genetics/Amgen Inc, working on genetic research unrelated to this project, Peter Nilsson: None declared, Francisco J. Blanco Grant/research support from: Lilly, Bristol MS, Pfizer

DOI: 10.1136/annrheumdis-2020-eular.4869

AB0206 CIRCULATING CENTROMERE PROTEIN F AUTOANTIBODIES FOR PREDICTING CLINICAL RESPONSE TO INFlixIMAB IN RHEUMATOID ARTHRITIS

L. Lourido1,2, C. Ruiz-Romero1,2, F. Picchi1, N. Diz-Rosales1, S. Vilaboa-Galán1, C. Fernández-López1, J. A. Pinto Tascande1, E. Perez-Pampin1, C. Regueiro Exposito1, A. Mera Varela1, A. Gonzalez2, K. Hambardzumyan3, S. Saevardsdottir3, P. Nilsson3, F. J. Blanco1,2, Gruppo di Investigación de Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidad da Coruña (UDC). As Xubias, 20009, A Coruña, Spain, A Coruña, Spain, B Coruña, Spain

Background: The presence of rheumatoid arthritis (RA) (1). Their presence is predictive for the development of RA (2). Anti-CarP antibodies are associated with the development of more severe forms of the disease in overall and anti-citrullinated peptide antibodies negative.
population of patients with RA (3). In the literature is still current the research which associate these antibodies with disease activity and functional status of patients.

**Objectives:** This study investigated the incidence of anti-CarP positive findings in patients with RA on synthetic and biologic disease-modifying therapy (DMT) and the relationship between anti-CarP antibody status and both disability and disease activity.

**Methods:** It was an open-label, observational, cross-sectional study. The trial included 70 patients with RA diagnosed on the basis of ACR 1987 and ACR / EULAR 2010 criteria, on treatment with synthetic and biological DMT, who attended the Clinic of Rheumatology, Military Medical Academy, from September to December 2018. The control group consisted of 18 healthy individuals. After approval of the institutional Ethical Committee and after patients have signed informed consent, the study was conducted. Disease activity score (DAS28) was determined for the assessment of RA activity, and the assessment of patients’ functional ability was performed using the Health assessment questionnaire disability index (HAQ-DI). Concentration of anti-CarP antibodies was determined by commercial ELISA anti-CarP quantitative sandwich immunoassay. The methods of descriptive and analytical statistics were used in statistical data processing.

**Results:** Based on the cut-off value (5.9 ng/ml), no one in the control group had positive anti-CarP antibodies, while 34.7% of the subjects with RA were positive. The positive correlation was found between anti-CarP antibody concentration and DAS28 in all RA patients (p = 0.0003; Pearson r = 0.4829). The positive correlation was also found between anti-CarP antibody concentration and HAQ-DI in all RA patients (p = 0.0003; Pearson r = 0.4253).

**Conclusion:** Anti-CarP antibodies were present in a significant number of patients with RA. This study demonstrated that patients with RA with higher concentrations of anti-CarP antibodies have higher disease activity and impaired functional status. It is undisputed that further and larger studies are needed to better determine the clinical significance of these antibodies.

**References:**


Graphs 1 and 2. Correlation of anti-CarP antibody concentration with DAS28 and HAQ-DI in all RA patients

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.4110

**AB0208**

**ASSOCIATION OF RHEUMATOID FACTOR, HLA-DRB1 SHARED EPITOPE (SE) AND SMOKING WITH RADIOGRAPHIC OUTCOME IN RHEUMATOID ARTHRITIS**

E. Mole, E. Mole1, A. Tarassia2, A. Tzioufas3, M. N. Manoussakis2, A. Tsirigiotis2, T. Alfanassiades3, V. Kitsou3, S. Gazi3, P. Vlachoyiannopoulos1, 1Kat General Hospital of Attica, Department of Rheumatology, Athens, Greece; 2Evangelismos Hospital, Immunology - Histocompatibility Department, Athens, Greece; 3University of Athens School of Medicine, Department of Pathophysiology, Athens, Greece

**Background:** Genetic and environmental factors interact in aetiopathogenesis of Rheumatoid Arthritis (RA). However, it remains unclear whether current smoking, presence of Rheumatoid factor (RF) and HLA-DRB1 SE influence the radiographic outcome.

**Objectives:** To clarify the possible associations between radiographic outcome, HLA-DRB1 SE, RF and smoking status in patients with longstanding RA.

**Methods:** An observational study of 240 consecutive Greek patients with RA, whose mean age and mean disease duration was 65.31±12.5 and 12.7±11.8 years respectively. Among them 74.17% were female, 40% were smokers, 60.42% had positive RF and 68.33% possessed at least one SE allele. HLA-DRB1 alleles were typed by molecular techniques (PCR-SSOP and SSP). X-rays of hands and feet were performed and scored by the Sharp-van der Hejde score (SHS) method.

**Results:** Results were stratified by RF and smoking status and analyzed by multivariate logistic regression. Overall, the mean SHS was significantly higher in RF positive than RF negative patients and in smokers than non-smokers (52.76±32.31 vs 38.4±31.96, p: 0.0007, 55.3±38.56 vs 28.8±22.32, p <0.0001, respectively). Furthermore, patients that possessed at least one SE allele had higher SHS than SE negative (35.49±24.76 vs 25.74±19.22, p: 0.0013). An association between radiographic severity and SE was found in RF positive patients. More specifically, seropositive patients carrying at least one SE allele had higher SHS than those lacking SE (40.85±33.21 vs 29.23±24.72, p: 0.037). On the other hand, smokers with at least one SE allele had higher SHS when compared to smokers without SE (29.27±25.20 vs 20.17±22, p: 0.048). Among RF negative and non-smokers RA patients, no significant association was found between the presence of HLA-DRB1 SE and radiographic severity.

**Conclusion:** Our data indicate that in longstanding RA there is an association between RF positivity, the presence of SE, current smoking status and radiographic outcome.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.4931